Article
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
BMC cancer - 17 Jul 2012
Mekenkamp Leonie J M, Tol Jolien, Dijkstra Jeroen R, de Krijger Inge, Vink-Börger M Elisa, van Vliet Shannon, Teerenstra Steven, Kamping Eveline, Verwiel Eugène, Koopman Miriam, Meijer Gerrit A, van Krieken J Han Jm, Kuiper Roland, Punt Cornelis J A, Nagtegaal Iris D
Abstract excerpt
BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. We assessed the influence of modification of KRAS by gene copy number aberration (CNA) and microRNAs (miRNAs) in correlation to clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.